Molecular Human Reproduction, Vol 3, 685-691, Copyright © 1997 by Oxford University Press
CA Anania, EA Stewart, BJ Quade, JA Hill and RA Nowak
Basic fibroblast growth factor (bFGF) is a regulator of angiogenesis which
is overexpressed in leiomyomas compared with matched myometrium. To
understand the physiological significance of this finding we characterized
the expression of the type 1 receptor for this ligand (FGFR1). Utilizing
reverse transcription-polymerase chain reaction (RT- PCR) we identified the
complete and alternatively spliced transmembrane forms and two secreted
forms of the FGFR1 in endometrium, myometrium and leiomyomas from all
patients. This is the first report of secreted forms in uterine tissue.
Proteins consistent with each of these isoforms were identified by Western
blot analysis in all three tissues. Immunohistochemistry revealed menstrual
cycle-specific regulation of FGFR1 protein in the endometrial stroma of
normal women but not in women with leiomyomas and abnormal uterine
bleeding. Stromal FGFR1 expression is suppressed in the early luteal phase
in normal women, but not in women with leiomyoma-related bleeding. These
findings support the role of the bFGF ligand-receptor system in the
pathogenesis of leiomyoma-related bleeding and may have implications for
fertility and contraception since the differential FGFR1 expression occurs
in the peri-implantation period of the early luteal phase.
JOURNAL ARTICLE
Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding
Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Okuda, K. Oshio, H. Shinmoto, A. Tanimoto, H. Asada, T. Fujii, Y. Yoshimura, and S. Kuribayashi Semiquantitative Assessment of MR Imaging in Prediction of Efficacy of Gonadotropin-releasing Hormone Agonist for Volume Reduction of Uterine Leiomyoma: Initial Experience Radiology, September 1, 2008; 248(3): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shushan, N. Rojansky, N. Laufer, B. Y. Klein, Z. Shlomai, R. Levitzki, Z. Hartzstark, and H. Ben-Bassat The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth Hum. Reprod., September 1, 2004; 19(9): 1957 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maruo, N. Ohara, J. Wang, and H. Matsuo Sex steroidal regulation of uterine leiomyoma growth and apoptosis Hum. Reprod. Update, May 1, 2004; 10(3): 207 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Moller, C. Rasmussen, B. Lindblom, and M. Olovsson Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle Mol. Hum. Reprod., January 1, 2001; 7(1): 65 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hague, L. Zhang, M. K. Oehler, S. Manek, I. Z. MacKenzie, R. Bicknell, and M. C. P. Rees Expression of the Hypoxically Regulated Angiogenic Factor Adrenomedullin Correlates with Uterine Leiomyoma Vascular Density Clin. Cancer Res., July 1, 2000; 6(7): 2808 - 2814. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Hennig, U. Deichert, U. Bonk, B. Thode, S. Bartnitzke, and J. Bullerdiek Chromosomal translocations affecting 12q14-15 but not deletions of the long arm of chromosome 7 associated with a growth advantage of uterine smooth muscle cells Mol. Hum. Reprod., December 1, 1999; 5(12): 1150 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Abulafia and D. M. Sherer ANGIOGENESIS OF THE ENDOMETRIUM Obstet. Gynecol., July 1, 1999; 94(1): 148 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hyder and G. M. Stancel Regulation of Angiogenic Growth Factors in the Female Reproductive Tract by Estrogens and Progestins Mol. Endocrinol., June 1, 1999; 13(6): 806 - 811. [Full Text]
|
|